Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 8/20 | 0.78 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.78 |
| ▸ | IDO1 | P14902 | 1/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | DAO | P14920 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | KDM1A | O60341 | 1/20 | 0.64 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29475123 | 1.00 | NPC1 (1.00) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| Hydrochloric Acid SCHEMBL16465542 | 0.98 | NPC1 (0.97) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL8769590 | 0.90 | NPC1 (0.82) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL16627058 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL6037548 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL19476163 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL17433428 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL27335879 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL7590295 | 0.88 | NPC1 (0.78) | NPC1RAB9ALMNASMN1; SMN2EGFR | |
| SCHEMBL5818325 | 0.86 | NPC1 (0.75) | NPC1RAB9ALMNASMN1; SMN2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | claimed |
| JP-2003508382-A | — | — | 2003-03-04 | — | — | JP | claimed |
| EP-1212296-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| WO-2001016097-A1 | PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| CN-117447381-A | Indole amide derivative and its application in preparing beta 2 Use of adrenoreceptor allosteric antagonist medicaments | 常州大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-109475521-B | Anti-proprotein convertase subtilisin Kexin type 9 (anti-PCSK 9) compounds and methods of use thereof for treating and/or preventing cardiovascular diseases | 实发生物医学公司 | 2022-11-15 | — | — | CN | disclosed |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2021-01-26 | — | — | US | disclosed |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | CE PHARM CO., LTD. (CN) | 2020-09-01 | — | — | US | disclosed |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | SHIFA BIOMEDICAL CORPORATION | 2020-08-20 | — | — | US | disclosed |
| CN-111171040-A | Dihydrofuropyran/pyridoindole derivatives and synthesis method thereof | 常州大学 | 2020-05-19 | — | — | CN | disclosed |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-09-05 | — | — | US | disclosed |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | CE PHARM CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| EP-3471714-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2019-04-24 | — | — | EP | disclosed |
| EP-3444031-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017222953-A1 | ANTI-PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 (ANTI-PCSK9) COMPOUNDS AND METHODS OF USING THE SAME IN THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2017177979-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | 中国科学院上海有机化学研究所 | 2017-10-19 | — | — | WO | disclosed |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | BYONDIS B.V. (NL) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10899748-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | NPC1 120/4885RAB9A 1970/4885LMNA 101/4885 |
| US-20200262822-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | NPC1 120/4885RAB9A 1970/4885LMNA 101/4885 |
| US-20190127337-A1 | HETEROCYCLIC CARBOXYLIC ACID AMIDE LIGAND AND APPLICATIONS THEREOF IN COPPER CATALYZED COUPLING REACTION OF ARYL HALOGENO SUBSTITUTE | AOC1, AOC2, AOC3 | NPC1 3545/4885RAB9A 2403/4885LMNA 4664/4885 |
| US-20110207767-A1 | Novel cc-1065 Analogs and Their Conjugates | PCNA, CDC5L, TOP1 | NPC1 3077/4885RAB9A 3318/4885LMNA 2883/4885 |
| US-10759765-B2 | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute | AOC1, AOC2, AOC3 | NPC1 3545/4885RAB9A 2403/4885LMNA 4664/4885 |
| US-20190270729-A1 | Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or Prevention of Cardiovascular Diseases | PCSK9, PCSK6, PCSK7 | NPC1 120/4885RAB9A 1970/4885LMNA 101/4885 |
| US-10947220-B2 | Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK6, PCSK7 | NPC1 120/4885RAB9A 1970/4885LMNA 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.